Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer, based on now-revealed data from the HER2CLIMB-05 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback